Survivin and tumorigenesis: Molecular mechanisms and therapeutic strategies

Journal of Cancer

Volumn 7, Issue 3, 2016, Pages 314-323

  Chen, Xun ^a   Duan, Ning ^a   Zhang, Caiguo ^b   Zhang, Wentao ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer; Cell cycle; Survivin; Therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA CATENIN; CANCER VACCINE; GENE THERAPY AGENT; IMMUNOMODULATING AGENT; INHIBITOR OF APOPTOSIS PROTEIN; NOTCH RECEPTOR; OLIGONUCLEOTIDE; PROTEIN INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL HYPOXIA; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; MOLECULAR PATHOLOGY; NEOPLASM; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84971552299     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13332     Document Type: Review

References (101)

1. Su Z, Yang Z, Xu Y, et al. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 2015; 14(1): 48.
2. Sun L, Peng Q, Qu L, et al. Anticancer agent icaritin induces apoptosis through caspase-dependent pathways in human hepatocellular carcinoma cells. Mol Med Rep. 2015; 11: 3094-100.
3. Zhang C, Liu Y. Targeting cancer with sesterterpenoids: the new potential antitumor drugs. J Nat Med. 2015; 69: 255-66.
4. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35: 495-516.
5. Zhang C, Zhang F. The Multifunctions of WD40 Proteins in Genome Integrity and Cell Cycle Progression. J Genomics. 2015; 3: 40-50.
6. Troy CM, Jean YY. Caspases: therapeutic targets in neurologic disease. Neurotherapeutics. 2015; 12: 42-8.
7. McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2013; 5: a008656.
8. Brady SW, Zhang J, Tsai MH, et al. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biol Ther. 2015; 16: 402-11.
9. Huang J, Lyu H, Wang J, et al. MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res. 2015; 5: 20-31.
10. Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014; 15: 2494-516
11. Saleem M, Qadir MI, Perveen N, et al. Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des. 2013; 82: 243-51.
12. Jarrin M, Mansergh FC, Boulton ME, et al. Survivin expression is associated with lens epithelial cell proliferation and fiber cell differentiation. Mol Vis. 2012; 18: 2758-69.
13. Ambrosini G, Adida C & Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997; 3: 917-21.
14. Fong WG, Liston P, Rajcan-Separovic E, et al. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics. 2000; 70: 113-22.
15. LaCasse EC, Baird S, Korneluk RG, et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998; 17: 3247-59.
16. Li J, Feng Q, Kim JM, et al. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology. 2001; 142: 370-80.
17. Lin JH, Deng G, Huang Q, et al. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun. 2000; 279: 820-31.
18. Tamm I, Kornblau SM, Segall H et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000; 6:1796-803.
19. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis. 2007; 12: 1543-68.
20. Luk SU, Xue H, Cheng H, et al. The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget. 2014; 5: 6896-908.
21. Kusner LL, Ciesielski MJ, Marx A, et al. Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study. PLoS One. 2014; 9: e102231.
22. Gu Y, Jin S, Wang F, et al. Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer. Biomed Pharmacother. 2014; 68: 471-5.
23. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer. 2010; 9: 75.
24. Carter BZ, Mak DH, Schober WD, et al. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006; 107: 1555-63.
25. Anandharaj A, Cinghu S, Park WY. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai). 2011; 43: 292-300.
26. Sehara Y, Sawicka K, Hwang JY, et al. Survivin Is a transcriptional target of STAT3 critical to estradiol neuroprotection in global ischemia. J Neurosci. 2013; 33: 12364-74.
27. Tang C, Lu YH, Xie JH, et al. Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis. Anticancer Drugs. 2009; 20: 249-58.
28. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998; 58: 5315-20.
29. Altieri DC. Cytokinesis, apoptosis and survivin: three for tango? Cell Death Differ. 2001; 8: 4-5.
30. Wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene family. Oncogene. 2004; 23: 8146-53.
31. Zhang L, Yan R, Zhang Q, et al. Survivin, a key component of the Wnt/beta-catenin signaling pathway, contributes to traumatic brain injury-induced adult neurogenesis in the mouse dentate gyrus. Int J Mol Med. 2013; 32: 867-75.
32. Bai H, Ge S, Lu J, et al. Hypoxia inducible factor-1alpha-mediated activation of survivin in cervical cancer cells. J Obstet Gynaecol Res. 2013; 39: 555-63.
33. Chen Y, Li D, Liu H, et al. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer Biol Ther. 2011; 11: 14-21.
34. Chen W, Zhong X, Wei Y, et al. TGF-beta Regulates Survivin to Affect Cell Cycle and the Expression of EGFR and MMP9 in Glioblastoma. Mol Neurobiol. 2015; DOI 10.1007/s12035-015-9121-6.
35. Chen Z, Sui J, Zhang F, et al. Cullin family proteins and tumorigenesis: genetic association and molecular mechanisms. J Cancer. 2015; 6: 233-42.
36. Zhang C. Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell. 2014; 5: 750-60.
37. Asanuma H, Torigoe T, Kamiguchi K, et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005; 65: 11018-25.
38. Zhu H, Zhang G, Wang Y, et al. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells. Cancer Sci. 2010; 101: 1156-62.
39. Vaira V, Lee CW, Goel HL, et al. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene. 2007; 26: 2678-2684.
40. Li Y, Xia ZL, Chen LB. HIF-1-alpha and survivin involved in the anti-apoptotic effect of 2ME2 after global ischemia in rats. Neurol Res. 2011; 33: 583-92.
41. Muller GA, Engeland K. The central role of CDE/CHR promoter elements in the regulation of cell cycle-dependent gene transcription. FEBS J. 2010; 277: 877-93.
42. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003; 3: 46-54.
43. Misso G, Di Martino MT, De Rosa G, et al. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014; 3: e194.
44. O'Connor DS, Wall NR, Porter AC, et al. A p34(cdc2) survival checkpoint in cancer. Cancer Cell. 2002; 2: 43-54.
45. Zhao J, Tenev T, Martins LM, et al. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000; 113 (Pt 23): 4363-71.
46. Hakonen E, Ustinov J, Palgi J, et al. EGFR signaling promotes beta-cell proliferation and survivin expression during pregnancy. PLoS One. 2014; 9: e93651.
47. Karar J, Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci. 2011; 4: 51.
48. Fernandez JG, Rodriguez DA, Valenzuela M et al. Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced beta-catenin/Tcf-Lef dependent transcription. Mol Cancer. 2014; 13: 209.
49. Wang H, Gambosova K, Cooper ZA, et al. EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic beta-cells. BMC Mol Biol. 2010; 11: 66.
50. Carter BZ, Milella M, Altieri DC, et al. Cytokine-regulated expression of survivin in myeloid leukemia. Blood. 2001; 97: 2784-90.
51. Zhang C, Zhang F. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell. 2015; 6: 88-100.
52. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003; 101: 1535-42.
53. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011; 30: 87.
54. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005; 5: 876-85.
55. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006; 25: 4798-811.
56. Ott M, Robertson JD, Gogvadze V, et al. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A. 2002; 99: 1259-63.
57. Brentnall M, Rodriguez-Menocal L, De Guevara RL, et al. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 2013; 14: 32.
58. Small S, Keerthivasan G, Huang Z, et al. Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia. 2010; 24: 1920-6.
59. Chandele A, Prasad V, Jagtap JC, et al. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 2004; 6: 29-40.
60. Wright ME, Han DK, Hockenbery DM. Caspase-3 and inhibitor of apoptosis protein(s) interactions in Saccharomyces cerevisiae and mammalian cells. FEBS Lett. 2000; 481: 13-8.
61. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003; 278: 23130-40.
62. Singh M, Chaudhry P, Fabi F, et al. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance. BMC Cancer. 2013; 13: 233.
63. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene. 2004; 23: 39-48.
64. Mita AC, Mita MM, Nawrocki ST, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14: 5000-5.
65. Beardmore VA, Ahonen LJ, Gorbsky GJ, et al. Survivin dynamics increases at centromeres during G2/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity. J Cell Sci. 2004; 117: 4033-42.
66. Dai D, Liang Y, Xie Z, et al. Survivin deficiency induces apoptosis and cell cycle arrest in HepG2 hepatocellular carcinoma cells. Oncol Rep. 2012; 27: 621-7.
67. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene. 2000; 19: 3225-34.
68. Chumakov PM. Function of the p53 gene: choice between life and death. Biochemistry (Mosc). 2000; 65: 28-40.
69. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003; 22: 9030-40.
70. Zhang C, Liu G, Huang M. Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition. Front Biol. 2014; 9: 104-13.
71. Lai YJ, Lin CI, Wang CL, et al. Expression of survivin and p53 modulates honokiol-induced apoptosis in colorectal cancer cells. J Cell Biochem. 2014; 115: 1888-99.
72. Hoffman WH, Biade S, Zilfou JT, et al. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002; 277:3247-57.
73. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002; 21: 2613-22.
74. Ulasov IV, Tyler MA, Zhu ZB, et al. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol. 2009; 34: 729-42.
75. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002; 21: 2613-22.
76. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13: 11-26.
77. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008; 4: 68-75.
78. Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2014; 106: djt356.
79. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011; 11: 393-410.
80. Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008; 27: 331-71.
81. Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med. 2007; 80: 51-60.
82. Wang YF, Ma SR, Wang WM, et al. Inhibition of survivin reduces HIF-1alpha, TGF-beta1 and TFE3 in salivary adenoid cystic carcinoma. PLoS One. 2014; 9: e114051.
83. Chen YQ, Zhao CL, Li W. Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer. J Exp Clin Cancer Res. 2009; 28: 9.
84. Qiao Q, Nozaki Y, Sakoe K, et al. NF-kappaB mediates aberrant activation of HIF-1 in malignant lymphoma. Exp Hematol. 2010; 38: 1199-208.
85. Benekli M, Baer MR, Baumann H, et al. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003; 101: 2940-54.
86. Carpenter RL, Lo HW. STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel). 2014; 6: 897-925.
87. Wang H, Holloway MP, Ma L, et al. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem. 2010; 285: 36129-37.
88. Allenspach EJ, Maillard I, Aster JC, et al. Notch signaling in cancer. Cancer Biol Ther. 2002; 1: 466-76.
89. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med. 2011; 208: 1931-35.
90. Chen Y, Li D, Liu H, et al. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer Biol Ther. 2011; 11: 14-21.
91. Lee CW, Raskett CM, Prudovsky I, et al. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008; 68: 5273-81.
92. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001; 29: 117-29.
93. Wahdan-Alaswad RS, Song K, Krebs TL, et al. Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling. Cancer Res. 2010; 70: 9106-17.
94. Song K, Shankar E, Yang J, et al. Critical role of a survivin/TGF-beta/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells. PLoS One. 2013; 8: e61896.
95. Yang J, Song K, Krebs TL, et al. Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced apoptosis and tumor progression. Oncogene. 2008; 27: 5326-38.
96. Bates DJ, Lewis LD. Manipulating the apoptotic pathway: potential therapeutics for cancer patients. Br J Clin Pharmacol. 2013; 76: 381-95.
97. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007; 28: 1133-9.
98. Pennati M, Colella G, Folini M, et al. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest. 2002; 109: 285-6.
99. Yamaki H, Nakajima M, Shimotohno KW, et al. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy. J Antibiot (Tokyo). 2011; 64: 635-44.
100. Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003; 102: 571-6.
101. Arber C, Feng X, Abhyankar H, et al. Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest. 2015; 125: 157-68.